I may have just missed it but I couldn't find any

Quote:

---

I may have just missed it but I couldn't find any mention of how often patients in the mCRC trial would be dosed

---

Quote:

---

TAS-102 and bevacizumab will be administered for three of four weeks in a four-week cycle, and leronlimab (at doses of 350 mg or 700 mg) will be administered weekly.
https://www.cytodyn.com/newsroom/press-releas...n-phase-ii

---